Èñ±ÍÀǾàÇ° Àü¹® ¹ÙÀÌ¿Àº¥Ã³ ³ëº§Æĸ¶°¡ ‘Á¦17ȸ ±¹Á¦ ¹ÂÄÚ´Ù´çÁõÇÐȸ(17th International Symposium on MPS and Related Diseases)'¿¡¼ GC³ì½ÊÀÚ¿Í °øµ¿¿¬±¸ °³¹ß ÁßÀÎ »êÇʸ®Æ÷ÁõÈıº AÇü(MPS IIIA) Ä¡·áÁ¦ ºñÀÓ»ó °á°ú¸¦ ¹ßÇ¥Çß´Ù.
±¹Á¦ ¹ÂÄÚ´Ù´çÁõÇÐȸ´Â À¯·´ ¹ÂÄÚ´Ù´çÁõ ȯ¿ìȸ¿¡¼ 3³â¸¶´Ù °³ÃÖÇÏ´Â ±¹Á¦ ½ÉÆ÷Áö¾öÀÌ´Ù. Èñ±ÍÁúȯ ºÐ¾ß ÀÇ·áÁø°ú Àü¹®°¡µéÀÌ ¸ð¿© Èñ±ÍÁúȯ¿¡ ´ëÇÑ ÃֽŠµ¿Çâ, »õ·Î¿î Ä¡·á¹ý, ÀÓ»ó ÁøÇàÇöȲ µîÀ» °øÀ¯ÇÑ´Ù. ȯÀÚ¿Í °¡Á·µéÀ» À§ÇÑ ´Ù¾çÇÑ ÇÁ·Î±×·¥, ³×Æ®¿öÅ· ÀÚ¸®µµ ¸¶·ÃµÇ¾î ÀÖ´Ù. ¿ÃÇØ´Â Áö³ 3ÀÏ(ÇöÁö½Ã°£)ºÎÅÍ 7ÀϱîÁö µ¶ÀÏ ºß¸£Ã÷ºÎ¸£Å©¿¡¼ ¿·È´Ù.
À̹ø Çà»ç¿¡´Â ¹Ì±¹, À¯·´, ¾Æ½Ã¾Æ Áö¿ªÀÇ MPS ÃÖ°í ±ÇÀ§ÀÚµéÀÌ Âü¼®Çß´Ù. ¡ã±¹Á¦ MPS Çùȸ(International MPS Society) ¡ã¹Ì±¹ ÃÖ´ë »êÇʸ®Æ÷ÁõÈıº ȯ¿ìȸÀÎ »êÇʸ®Æ÷ Ä¡·á±â±ÝÇùÀÇȸ(Cure Sanfilippo Foundation) ¡ãÀ¯·´ MPS Çùȸ µî ¼¼°è ¹ÂÄÚ´Ù´çÁõ °ü·Ã Çùȸ ÁÖ¿ä ÀÓ¿øµé°ú °ü°èÀڵ鵵 ´ë°Å Âü°¡Çß´Ù.
¹ßÇ¥ÀÚ·Î ³ª¼± ¾ç¾Æ¶÷ °ºÏ»ï¼ºº´¿ø ¼Ò¾Æû¼Ò³â°ú ±³¼ö´Â ³ëº§Æĸ¶°¡ ÇöÀç ÁøÇà ÁßÀÎ MPS IIIA ÇÁ·ÎÁ§Æ® ‘³ú½Ç ³» È¿¼ÒÄ¡·á¸¦ ÅëÇÑ MPS IIIA Ä¡·áÁ¦ °³¹ß(Therapeutic potential of intracerebroventricular recombinant human Heparan-N-Sulfatase enzyme replacement therapy in MPSIIIA mice)’ ºñÀÓ»ó ¿¬±¸°á°ú¸¦ °ø°³Çß´Ù. ÇØ´ç ¿¬±¸´Â ÃÖ¿ì¼ö Æ÷½ºÅÍ(Best Poster)·Î ¼±Á¤µÅ ÃÖ¿ì¼ö Æ÷½ºÅÍ ¼¼¼Ç(Best of Poster Session)¿¡¼µµ ¼Ò°³µÆ´Ù.
MPS IIIA´Â À¯ÀüÀÚ °áÇÔÀ¸·Î ÀÎÇØ Ã¼³»¿¡ ÇìÆĶõ Ȳ»ê¿°ÀÌ ÃàÀûµÇ´Â ¿¼º À¯ÀüÁúȯÀÌ´Ù. ´ëºÎºÐ ȯÀÚ°¡ 15¼¼ ÀüÈÄ »ç¸ÁÇÏ´Â ÁßÁõ Èñ±ÍÁúȯÀÌÁö¸¸ ¾ÆÁ÷ Çã°¡ ¹ÞÀº Ä¡·áÁ¦°¡ ¾ø´Ù.
³ëº§Æĸ¶ °ü°èÀÚ´Â "À̹ø ½ÉÆ÷Áö¾ö¿¡¼ MPS IIIA Ä¡·áÁ¦¿¡ ´ëÇÑ ¼Ò°³, ¿¬±¸°³¹ß ¹× ÀÓ»ó ÇöȲÀ» °ø°³ÇÏ°í ÃÖ¿ì¼ö Æ÷½ºÅÍ·Î »ÌÈ÷´Â ¼º°ú¸¦ °Åµ×´Ù"¸ç "Èñ±ÍÁúȯ ºÐ¾ß ÃÖ°í Àü¹®°¡ÀÎ Æú Çϸ¶Ã÷(Paul Harmatz), ÁÙ¸® ¾ÆÀÌÁ¨°¡¸£Æ®(Julie Eisengart), Ä«¶ó¿À³Ú(Cara O’neal) ¹Ì±¹ »êÇʸ®Æ÷ ȯ¿ìȸÀå µî Èñ±ÍÁúȯ ºÐ¾ß ±Û·Î¹ú KOL(Key Opinion Leader)µé°ú ±Û·Î¹ú ÀÓ»ó¿¡ ´ëÇØ ½Éµµ ±íÀº ³íÀǵµ ³ª´³´Ù"°í ¸»Çß´Ù.
À̾î "¿ì¼öÇÑ ºñÀÓ»ó ¿¬±¸°á°ú¸¦ Åä´ë·Î ±Û·Î¹ú ÀÓ»ó Áغñ¿¡ ¸¸ÀüÀ» ±âÇØ ¼¼°è ÃÖÃÊ MPS IIIA Ä¡·áÁ¦¸¦ °³¹ßÇÏ°Ú´Ù"°í µ¡ºÙ¿´´Ù.
¹Úº´¿ì ±âÀÚ bwpark0918@pharmstock.co.kr
<ÀúÀÛ±ÇÀÚ © ÆʽºÅ¹, ¹«´Ü ÀüÀç ¹× Àç¹èÆ÷ ±ÝÁö>